Alimera Sciences Inc

Alimera Sciences — Q1 2018 Earnings Presentation

13 slides from Alimera Sciences's earnings presentation, May 3, 2018

  1. Slide 1: First Quarter 2018 Earnings Presentation

    First Quarter 2018 Earnings Presentation Thursday, May 3rd 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things,, the potential approval and commercialization of ILUVIEN for the treatment of posterior uveitis in Europe. Such forward-looking statemen

  3. Slide 3: First Quarter 2018 Overview

    3 First Quarter 2018 Overview Significant Revenue Growth • 48% increase compared to 1Q17 © 2018 Alimera Sciences | NASDAQ: ALIM U.S. • $7.0 million in 1Q18; 59% revenue increase in the U.S. compared to 1Q17 • 21% increase in end user demand International • $2.8 million in 1Q18 • 27% revenue increase

  4. Slide 4: ILUVIEN Presentations at ARVO

    4 ILUVIEN Presentations at ARVO* © 2018 Alimera Sciences | NASDAQ: ALIM 19 ILUVIEN presentations at ARVO 2018 Data from multiple countries represented • Eight U.S. presentations on diabetic macular edema (DME) • Ten EU/Middle East Presentations on DME • One European presentation on uveitis Real worl

  5. Slide 5: ILUVIEN for Non-Infectious Posterior Uveitis

    5 ILUVIEN for Non-Infectious Posterior Uveitis 90.5% 59.6% 27.6% 25.7% PSV-FAI-001 PSV-FAI-005 Percentage of Patients with Uveitis Recurrence FAI InsertSham • Application for non-infectious posterior uveitis indication submitted in 17 countries in Europe in December of 2017. • Alimera plans to file

  6. Slide 6: Growth of ILUVIEN Usage in United States

    6 Growth of ILUVIEN Usage in United States © 2018 Alimera Sciences | NASDAQ: ALIM 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 ~Cumulative Eyes Treated with ILUVIEN - U.S.

  7. Slide 7: U.S. Distributor and Demand Orders

    7 U.S. Distributor and Demand Orders © 2018 Alimera Sciences | NASDAQ: ALIM 167 467 536 502 533 777 788 827 705 850 837 896 851 293 460 608 475 501 873 750 1004 500 980 864 804 853 0 200 400 600 800 1000 1200 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 Demand Revenue Distributor

  8. Slide 8: U.S. Demand Orders

    8 U.S. Demand Orders © 2018 Alimera Sciences | NASDAQ: ALIM 167 467 536 502 533 777 788 827 705 850 837 896 851 0 100 200 300 400 500 600 700 800 900 1000 First Quarter Second Quarter Third Quarter Fourth Quarter 2015 2016 2017 2018 U.S. End User Demand • Units sold from our distributor partners to

  9. Slide 9: Income Statement

    9 Income Statement © 2018 Alimera Sciences | NASDAQ: ALIM ($000’s) Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Revenue $9,802 $6,618 Operating Expenses $13,295 $11,542 Net Loss ($7,684) ($6,735) Adj. EBITDA* ($2,913) ($3,679) *Adjusted EBITDA is earnings before interest taxes

  10. Slide 10: First Quarter 2018 Overview

    10 First Quarter 2018 Overview Significant Revenue Growth • 48% increase compared to 1Q17 © 2018 Alimera Sciences | NASDAQ: ALIM U.S. Revenue • $7.0 million in 1Q18; 59% revenue increase in the U.S. compared to 1Q17 • 21% increase in end user demand International • $2.8 million in 1Q18 • 27% revenue

  11. Slide 11: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    11 Reconciliation of GAAP Net Loss to NON-GAAP Adjusted EBITDA © 2018 Alimera Sciences | NASDAQ: ALIM Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GA

  12. Slide 12: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    12 Reconciliation of GAAP Net Loss to NON-GAAP Adjusted EBITDA © 2018 Alimera Sciences | NASDAQ: ALIM Three Months Ended March 31, ($000’s) 2018 2017 GAAP Net Loss ($7,684) ($6,735) Adjustments to Net Loss Interest Expense, Net and Other $1,151 $1,337 Provision for Taxes - $26 Depreciation and Amort

  13. Slide 13: First Quarter 2018

    First Quarter 2018 Earnings Presentation Thursday, May 3rd 2018

Alimera Sciences — Q1 2018 Earnings Presentation on 6ix